PBG BioPharma Inc. receives GMP Manufacturing Site Licence for NHPs

1.7 min readPublished On: September 29th, 2021By

LEDUC, AB  – PBG BioPharma Inc., (PBG), a Phytochemical Biopharmaceutical Group company, announced that it has received a manufacturing Site License issued by the Natural and Non-Prescription Health Products Directorate (NNHPD) of Health Canada for the manufacturing, packaging and labeling of natural health products at its facility in Leduc, Alberta.

This licence allows PBG to diversify its GMP-compliant manufacturing business through the addition of natural health products including nutraceuticals, herbal remedies, vitamins, minerals and other non-prescription over the counter therapeutics to its current Health Canada licensed Hemp and Cannabis related processing/manufacturing and analytical business.

PBG’s 25,000 square foot state-of-the-art biopharmaceutical facility houses multiple purpose-built manufacturing units and analytical/research laboratories, including a suite of GMP compliant and ISO 17025 accredited laboratories for analytical testing, research and formulation development for natural health products, nutraceutical, hemp/cannabis and special herbal products, a Health Canada licensed GMP cannabis/hemp processing and manufacturing facility, and a separate GMP NHP manufacturing unit. Each functional unit occupies a dedicated space in the facility that is separate from other functional units. Together this facility serves as a one-stop-shop for companies looking to develop, test and manufacture high-quality science based natural health and/or hemp/cannabis products.

This site licence confirms that PBG has demonstrated Good Manufacturing Practices, meaning exemplary manufacturing, labelling, importing, and handling and storage conditions and procedures are in place to “ensure an effective overall approach to product quality control and risk management”.

Utilizing its cornerstone GenBioChem® Triple Fingerprinting Technology, PBG strives to meet the highest scientific and quality standards in its scientific and manufacturing practice.

“Receiving this critical natural health product manufacturing site licence signifies another major milestone our company has achieved. We are now in a better position to develop and commercialize science-based nutraceuticals and herbal medicines and to serve other NHP industries looking to manufacture and launch their own innovative natural health products”, said Dr. Jacqueline Shan, Founder, President and CEO of PBG BioPharma Inc.

(This information is primarily sourced from PBG BioPharma Inc.  Highly Capitalized has neither approved nor disapproved the contents of this news release. Read our Disclaimer here).

About the Author: News Team

Newsteam at Highly Capitalized are some of the most experienced writers in cannabis and psychedelics business & finance. We cover capital markets, finance, branding, marketing and everything important in between. Most of all, we follow the money.

Share This Story, Choose Your Platform!

Latest News

  • Ayr Wellness

Ayr Wellness Brings Cannabis Brand LIT To Massachusetts

August 4th, 2022|

MIAMI - Ayr Wellness Inc. (CSE: AYR.A, OTCQX: AYRWF), a U.S. multi-state cannabis operator, announced that it has expanded its extensive branded-product portfolio with the flower brand, LIT. LIT originally launched in Nevada, produced by ...

PharmaCielo Announces First Shipment to Mexican Joint Venture Partner

August 4th, 2022|

TORONTO and RIONEGRO, Colombia–PharmaCielo Ltd. (TSXV: PCLO) (OTCQX: PCLOF), the Canadian parent of Colombia's premier cultivator and producer of dried flower and medicinal-grade cannabis extracts, PharmaCielo Colombia Holdings S.A.S.,  today announced its first shipment of ...